mRNA Vaccines and Therapeutics Market Size is projected to reach USD 58.92 billion by 2031, growing at a CAGR of 13.3%: Straits Research
June 08, 2023 11:00 ET
|
Straits Research
New York, United States, June 08, 2023 (GLOBE NEWSWIRE) -- mRNA-based therapeutics and vaccines permit the combination of desirable immunological properties. These are manufactured in the laboratory...
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
June 02, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
May 31, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Kinarus Therapeutics Group Reports 2022 Annual Results
May 31, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022Clinical efforts re-focused on developing KIN001 for original indications IPF and wet AMDCDIM CHF1.5...
Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine
May 24, 2023 11:28 ET
|
Be The Match
MINNEAPOLIS, May 24, 2023 (GLOBE NEWSWIRE) -- Results from a joint study between CIBMTR® (Center for International Blood and Marrow Transplant Research®)—a research collaboration between the...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
May 15, 2023 08:45 ET
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
May 11, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
May 05, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Audited full year 2022 annual financial figures due to be reported by end of May 2023 Basel, Switzerland, May 5, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage...
International Covid Memorial Monument Design Competition Underway
May 02, 2023 11:57 ET
|
The Hektoen Institute COVID-19 Monument Commission
CHICAGO, May 02, 2023 (GLOBE NEWSWIRE) -- An international design competition is underway for a Covid memorial monument. The winning design will be awarded $20,000 USD. A distinguished panel of...
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report
April 28, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Ad hoc announcement pursuant to Art. 53 LR Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report Basel, Switzerland, 28...